N. Karachaliou

发表

LBA52 Tepotinib + osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study

C. Dooms, F. de Marinis, J. Mazières, 2022, Annals of Oncology.

EP08.02-162 Tepotinib with an EGFR-Tyrosine Kinase Inhibitor (TKI) in Patients with EGFR-mutant MET-amplified NSCLC: A Case Series

J. Mazières, L. Tho, X. Le, 2022, Journal of Thoracic Oncology.

75P Inhibition and exploitation of aldehyde dehydrogenase 1 (ALDH1) as a cancer stem cell marker in cisplatin resistant NSCLC

K. O'Byrne, R. Rosell, S. Pilotto, 2016 .